The microbiome of diverticulitis
The microbiome of diverticulitis
复制标题
DOI：
10.1016/j.cophys.2021.06.006
复制
发表时间：
2021-07-10
影响因子：
2.5
通讯作者：
Koltun, Walter A.
中科院分区：
文献类型：
--
作者：
Jeganathan, Nimlan Arjun;Davenport, Emily R.;Koltun, Walter A.
尽管在患者痛苦和医疗保健支出方面对社会产生了显著影响，但结肠憩室炎的病理生理学研究文献相对较少。根据初步研究，类似于其他胃肠道疾病，微生物组的改变似乎与憩室炎有关。事实上，当比较同一个体内患病和未患病结肠组织的片段时，可以检测到微生物组中的这些扰动。不幸的是，如果没有纵向研究，区分因果关系是不可行的。虽然使用抗生素治疗单纯性憩室炎正在减少，但利用利福昔明，益生菌甚至粪便微生物群移植的研究正在增加。目前，治疗建议受到研究人群显著异质性和混杂偏倚的限制。最终，虽然生态失调可能在憩室炎中发挥作用，但缺乏进行机制研究的动物模型限制了循证建议。
Despite a marked impact on society in terms of patient suffering and healthcare expenditure, colonic diverticulitis has a relative scarcity of published literature examining its pathophysiology. Based on preliminary studies, akin to other gastrointestinal diseases, alterations of the microbiome appear to be associated with diverticulitis. In fact, these perturbations in the microbiome can be detected when comparing segments of diseased and non-diseased colonic tissues within the same individual. Unfortunately, differentiating cause from effect is not feasible without longitudinal studies. While the use of antibiotics for the treatment of uncomplicated diverticulitis is waning, studies utilizing rifaximin, probiotics, and even fecal microbiota transplantation are growing. At present, treatment recommendations are limited by significant heterogeneity in the study populations as well as confounding bias. Ultimately, while dysbiosis is likely to play a role in diverticulitis, a lack of animal models upon which to perform mechanistic study has limited evidence-based recommendations.